|
Market Cap (22-May) $1,644,114,176 (454th) |
Close (30-Jun) $12.25 |
Volume (30-Jun) 261,029 |
Shortsold (5-May) 7,255,072 (5.76%) (39th) |
|
52w High $24.00 |
52w Low $8.61 |
P/E 75.19 |
EPS 1.09 |
NEU released this announcement to the ASX on 19 November 2020, 9:11. The announcement is marked as price sensitive, and is 2 page(s) in length and 129.76kb in size.
You can view all announcements from NEU and see how they appear on a price chart on the announcements page.
At the date of this announcement, NEU was 0.076% short sold according to ASIC data. It was ranked the 437th most shorted stock on the ASX. It is now ranked as the 39th most shorted stock on the ASX with 5.756% of total shares short sold as of the latest reported data (05 May 2025).
| Other Recent Announcements from NEU | |
|---|---|
| Neuren completes enrolment in Phelan-McDermid Phase 2 trial | 30 June 2023, 9:36 |
| Neuren opens first site in US for Prader-Willi Phase 2 trial | 28 June 2023, 9:55 |
| Change of Director's Interest Notice | 14 June 2023, 18:44 |
| Neuren receives US$40m milestone payment | 7 June 2023, 15:19 |
| Neuren presenting at Jefferies Global Healthcare Conference | 5 June 2023, 16:32 |
| Approval received for final stage of NNZ-2591 clinical trial | 19 November 2020, 9:11 |
| Quarterly report and cash flow statement for Q3 2020 | 29 October 2020, 9:50 |
You must be logged in to post a reply.
Neuren Pharmaceuticals 